pharma · Graft Rejection · Arrhythmias
Wyeth is now
Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now is a pharma organization headquartered in CN. Primary therapeutic focus areas include Graft Rejection, Arrhythmias, Depressive Disorder, Major, Rheumatoid Arthritis, Hemophilia A. NovaPharmaNews links 9 clin
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 9
- Drugs
- 8
- Patents
- 0
Double-blind investigational anti-arrhythmic
Phase 2 · small molecule · Arrhythmias
Double-blind investigational anti-arrhythmic for Arrhythmias is a Phase 2 program (small_molecule) at Wyeth is now a wholly owned subsidiary of Pfizer with 1 ClinicalTrials.gov record(s).
Internal code 3163K1-200
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Arrhythmias
- Status
- terminated
- Trials
- 1